Ipamorelin 10 mg
Ipamorelin 10 mg is a selective pentapeptide GHSR agonist that triggers pulsatile growth-hormone release with minimal ACTH or cortisol elevation. Supplied as a 10 mg lyophilised peptide vial for controlled PK/PD and GH-axis research. For laboratory use only.
€ 39.00
Description
Ipamorelin 10 mg — Sterling Knight Pharmaceuticals
Brand: Sterling Knight Pharmaceuticals
Category: Injectable Peptide · Growth Hormone Secretagogue (GHSR Agonist)
Content: 10 mg Ipamorelin (lyophilised powder)
Packaging: 1 sterile vial in carton
Origin: United Kingdom
Price: €39
Research Notice: Laboratory research only. Not for human or veterinary use.
🧬 Product Overview
Ipamorelin is a pentapeptide and highly selective ghrelin-receptor (GHSR1a) agonist, engineered to stimulate growth hormone (GH) release with minimal impact on ACTH or cortisol pathways.
Compared with older GHRPs (e.g., GHRP-2, GHRP-6), ipamorelin exhibits cleaner GH targeting and is widely used as a reference model in endocrine, PK/PD, and anti-doping research.
- Strong GH-specific secretagogue action
- Minimal adrenal-axis activation (cortisol/ACTH)
- Well-characterized PK profile (t½ ~2 hours)
- Fast, predictable GH peak (~0.67 hours post-dose)
- WADA-prohibited under peptide hormones (S2)
🔬 Key Research Highlights
Mechanism:
Ipamorelin (Aib–His–D-2-Nal–D-Phe–Lys-NH₂) binds GHSR1a, producing pulsatile GH release through hypothalamic/pituitary signalling.
Selectivity:
Human studies demonstrate no significant ACTH or cortisol elevation at doses far above GH-effective levels — a major advantage over other GHRPs.
PK/PD:
Terminal half-life ≈ 2 hours, with a clear GH peak ~0.67 hours post-administration.
Sport status:
All GH secretagogues and GHSR agonists are WADA S2 prohibited substances.
🧬 Mechanism of Action (Simplified)
- Selective binding to GHSR1a → GH secretion
- Triggers pulsatile GH release without broad pituitary stimulation
- Minimal ACTH/cortisol elevation → “clean” GH-axis targeting
- Short half-life allows precise PK/PD modelling
📊 Technical Specification Table
| Field | Data |
|---|---|
| Chemical name | Ipamorelin |
| Chemical formula | C38H49N9O5 |
| Synonyms | NNC-26-0161 · Aib-His-D-2-Nal-D-Phe-Lys-NH₂ · Ipamorelin acetate |
| Molecular weight | ~711.8 g/mol |
| CAS number | 170851-70-4 |
| Literature highlights |
Selective GHSR agonist; Minimal ACTH/cortisol response; GH peak ~0.67 h; half-life ~2 h. |
| Total active content | 10 mg per vial |
| Storage / stability | Store cool, protected from light; stable ≈ 36 months sealed (see COA/SDS). |
| Country of origin | United Kingdom |
📚 Research Context & Applications
- GH pulse modelling and IGF-1 axis studies
- Short half-life PK/PD simulations
- Comparative GHSR agonist profiling
- Anti-doping detection method development
⚠️ Side Effects / Risks (Class-Based)
- GH/IGF-1–related effects (e.g., headache, fluid retention)
- Potential endocrine disruption with repeated exposure
- Peptide must be handled using proper PPE
- Positive doping test risk under WADA S2
🧯 Compliance Notice
FOR RESEARCH USE ONLY.
Not for human or veterinary use. Not a medicine, supplement, or therapeutic compound.
Researchers must follow institutional biosafety procedures and SDS handling.
WADA Status: Prohibited under S2 — peptide hormones, growth factors, and releasing factors.
There are no reviews yet.
